Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
Biothera Presents Phase IIb NSCLC Data
The company gave a presentation about its randomized trial in patients with previously untreated advanced non-small cell lung cancer (NSCLC) evaluating Biothera’s immunotherapy drug, Imprime PGG®. The study met its primary endpoint and showed a statistically significant improvement in objective response rate, more than double that of the control group. [Press release from Biothera discussing research presented at the European Lung Cancer Conference 2014, Geneva]